Latest Updates
Paragard mass tort marketing has entered a buyer's market following Teva's bellwether trial victory in July 2025, creating a measurable shift in case acquisition costs and competitive intake volume. Firms that paused spending after the verdict have reduced demand, which is compressing cost-per-case for attorneys willing to re-enter now. Understanding the current MDL posture, claimant pool size, and litigation trajectory is essential before committing or reallocating budget.
Why Paragard IUD Is a Business Opportunity Worth Watching Right Now
Paragard is a copper intrauterine device that has been on the market for decades. The core allegation across thousands of filed cases is that the device breaks during removal, leaving fragments of the plastic arms inside the uterus or migrating elsewhere in the body, causing pain, additional surgery, and in some cases permanent injury. The device does not use hormones, which gives it a distinct user demographic: women who specifically sought a hormone-free option, often younger and health-conscious, a group that is relatively reachable through digital advertising.
The FDA has issued enforcement-level recall notices tied to Paragard manufacturing lots as recently as March 2026. Recalls are not automatic proof of liability, but they are meaningful for advertising and intake because they create a new news cycle that prompts women to check whether their device is affected. That recurring news peg gives firms a reason to keep campaigns warm even during quieter litigation phases.
The Jacob Score for Paragard currently sits at 52 out of 100, with science and momentum rated as developing and verdicts rated weak. That 52 tells a real story. The underlying injury mechanism is plausible and documented, but the first bellwether verdict went to the defense, and that weakness in the verdicts dimension pulls the overall score down. A 52 is not a score that says "flood the zone." It is a score that says "watch carefully, size your position carefully, and be selective about what cases you retain."
The Litigation Landscape: MDL Status, Bellwether Results, and What They Mean for Case Value
The Paragard MDL is pending in the Northern District of Georgia. Case transfers continue, as evidenced by the Simon v. Cook transfer to the MDL court in late March 2026. The MDL machinery is still actively consolidating cases, which means discovery and Daubert battles are ongoing and a second bellwether trial has not yet been scheduled at the time of this writing.
Teva's win in the first bellwether on March 13, 2026 was significant. Defense wins in bellwethers are not unusual, and a single verdict does not end mass tort litigation. Look at what happened after early defense wins in talc or 3M earplugs. What they do accomplish is suppress plaintiff settlement leverage, at least temporarily. Teva also moved immediately for an interlocutory appeal on preemption grounds, which is a litigation tactic designed to freeze momentum. The judge denied the motion to pause trial proceedings, so Teva was not able to use the appeal as a delay mechanism, but the preemption argument is still alive and it represents a real legal risk that any firm holding these cases needs to price in.
For firm economics, the bellwether result means a few things. First, settlement is not imminent. Firms signing cases today should underwrite a multi-year hold, likely three to five years before any meaningful resolution fund materializes. Second, case selection is now more important than raw volume. The firms that will come out ahead are those with well-documented cases where the fracture is clearly evidenced in imaging and the injury required surgical intervention. Thin cases are going to be harder to move in any eventual resolution. Third, cost per signed case is likely to compress somewhat as less sophisticated buyers pull back in the wake of the defense verdict, which is actually a buying opportunity for well-capitalized firms with the appetite and the infrastructure to hold.
The Claimant Pool and Demand Side: Is There Still Volume to Capture?
Paragard has been implanted in millions of American women since its approval. Estimates of the addressable plaintiff pool vary, but the relevant subgroup is women who had a Paragard removed and experienced device fracture with resulting documented injury. That is a narrower pool than the total implant population, which is actually a good thing for case quality. You are not chasing a vague causation story across an enormous population. You are looking for a specific, documentable event.
Geographic concentration is not dramatically skewed the way some torts are. Paragard was marketed and prescribed broadly across OB-GYN practices nationwide. Urban and suburban markets tend to show higher case density simply because of population size, but rural practices also implanted the device. You are not limited to a handful of states the way you might be with a regional drug or a workplace exposure tort.
Saturation is moderate. This is not a tort where the plaintiff bar saturated the market three years ago and the qualified claimants who were reachable have already been signed. The defense verdict may have slowed some firms, but it also means a portion of the signed-case inventory that was sitting with underfunded firms could become available at a discount through case acquisition. For firms that prefer to buy rather than advertise, now is a reasonable time to evaluate acquisition pricing from firms looking to exit the space.
Paragard Mass Tort Marketing: Advertising Economics and Channel Strategy
Let me give you the real acquisition numbers as they stand today. Cost per lead on Paragard through paid social, primarily Meta, runs roughly in the $80 to $180 range depending on targeting specificity and creative quality. These are not hot, consumer-recognized tort names the way NEC baby formula or AFFF were at their peaks. You have to do more educational work in the creative to get a qualified lead to identify herself and respond.
Cost per signed retainer, after intake screening, typically runs in the $1,200 to $2,500 range for firms running efficient campaigns with solid intake operations. That range widens significantly if your intake team is slow, your retainer process has friction, or you are not qualifying hard on the front end. Firms that cut corners on intake end up paying $4,000 or more per signed case when you account for the wasted spend on leads that never convert or convert into cases that get kicked later.
Meta is the primary channel because the demographic, women ages 25 to 50 who were on a hormone-free birth control method, is reachable on Facebook and Instagram with reasonable precision. The creative angles that convert best are not fear-based. The strongest hooks are informational: "Paragard was recalled. Here is what that means." Combined with messaging around a specific removal injury, that framing generates qualified responses without burning the audience. Search through Google is a secondary channel, useful for capturing women who are already actively researching, but the volume is lower and the cost per click is competitive because multiple firms are bidding on the same keywords.
Effective Paragard mass tort marketing right now requires patience in the creative testing phase. This is not a set-it-and-forget-it tort. You need to be monitoring frequency, rotating creative, and adjusting targeting monthly.
Intake and Qualification: What Makes a Paragard Case Stick
On the firm side, intake for Paragard is more specific than many torts. The screening questions that matter are: Did the claimant have a Paragard IUD? Was the IUD removed or attempted to be removed? Did the device fracture or break during removal? Was the fracture confirmed by imaging, a physician note, or a surgical record? What injury resulted, and was any additional medical procedure required?
Cases with documented fracture plus a surgical procedure to remove fragments are your strongest files. Cases where the claimant reports pain but has no imaging or medical records confirming fracture are much weaker and will likely not survive any eventual case vetting process during MDL discovery. Sign what you can prove, not what you suspect.
The retainer flow works best when intake is reaching out within minutes of a lead coming in. Response time degradation from five minutes to two hours drops conversion rates dramatically on digital-sourced leads. If your intake team is not staffed to respond quickly during peak hours, you are leaving signed cases on the table. AI-assisted intake tools are starting to close this gap for some firms, handling the initial screening questions and keeping the lead warm until a human intake specialist is available. For firms interested in how AI fits into intake operations more broadly, I covered this in "A Lawyer's Guide to AI."
How MTAA Runs Paragard Campaigns
At Mass Tort Ad Agency, we have managed over $250 million in Facebook ad spend across more than 600 plaintiff law firms and 100-plus torts. Paragard is one of the torts we actively manage for clients on our cost-plus model: you pay actual ad spend plus a 15% management fee, with full transparency into what is being spent and what it is producing.
Our approach to Paragard right now is deliberate. Given the bellwether result and the Jacob Score sitting at 52, we are advising clients to run campaigns at a controlled scale rather than aggressive volume, with a strong emphasis on intake quality over raw lead count. We are watching the preemption appeal closely. If that appeal fails and the second bellwether is scheduled with a stronger plaintiff case, the score and the strategy will shift, and so will our clients' budgets.
We build the creative, manage the targeting, report on performance in real time, and adjust based on what the data shows. Firms that have tried to run Paragard internally typically see cost per signed case 40 to 60 percent higher than what we produce because the creative testing and audience management require hands-on daily work that most internal marketing teams are not structured to deliver.
The Bottom Line on Paragard Right Now
This is not a tort to abandon because of one defense verdict. It is also not a tort to chase blindly with a large uncapped budget. The honest read is that Paragard is a case-acquisition opportunity for selective, well-capitalized plaintiff firms that can hold cases for three to five years and are rigorous about signing only well-documented files. Paragard mass tort marketing at this stage rewards discipline over volume. Run campaigns at a scale that keeps your pipeline warm and your intake team sharp, invest in qualifying your cases hard on the front end, and keep a close eye on the second bellwether scheduling and the preemption argument as the litigation develops. If you want to talk through the acquisition math or get a campaign built around your firm's specific intake capacity, that is exactly what MTAA is set up to do.
Ready to Build Your Caseload?
Get a free campaign analysis from Mass Tort Ad Agency.
$250M+ in mass tort Facebook ad spend. 600+ law firms served. Transparent cost-plus pricing with no hidden fees.
Schedule a Free Consultation →Frequently Asked Questions: Advertising Paragard IUD Cases
What do current Paragard IUD case acquisition costs look like after the first bellwether loss, and are the economics still viable for plaintiff firms?
Following Teva's win in the first bellwether trial, early indications suggest cost per signed case has softened as some firms pause intake, which can create a discounted acquisition window for firms with capital and risk tolerance. The economics depend heavily on your fee structure, case quality filters, and whether you plan to retain or refer, but firms acquiring now at reduced CPCs are betting the litigation climate shifts favorably before the docket resolves. Running a cost-plus model against projected settlement tiers and realistic attrition rates is the right framework before committing budget at any scale.
How large is the available Paragard claimant pool, and is there still meaningful volume to capture or has the market saturated?
Paragard has been on the U.S. market since 1984 and has been used by millions of women, and the MDL currently holds thousands of filed cases, suggesting the docket is active but not yet in a late-stage exhaustion phase. The FDA's March 2026 manufacturing recall notices signal continued device presence in the market, meaning new potential claimants are still being created, not just drawn from a static historical pool. For plaintiff firms evaluating entry, there is still capturable volume, but the competitive intensity among acquiring firms will determine whether your intake pipeline yields sufficient case quality at acceptable cost.
Which advertising channels are most effective for Paragard IUD plaintiff acquisition, and how should firms structure their media mix?
Meta and YouTube have historically been the highest-volume channels for Paragard case acquisition due to the device's identifiable user demographic, specifically younger women who sought hormone-free contraception and are reachable through interest and behavioral targeting. Search intent on Google remains a strong qualifier for warm leads already researching the device's safety, making paid search a useful complement for capturing bottom-funnel volume. A cost-plus advertising model, where your vendor is paid on verified acquisition metrics rather than raw ad spend, provides the most accountability and aligns incentives with signed-case output rather than impression delivery.
How should plaintiff firms interpret the first Paragard bellwether verdict from a litigation strategy and portfolio management standpoint?
A single defendant verdict in a bellwether trial is meaningful signal but not a litigation-ending event; MDL bellwether trials are designed to test arguments and expose weaknesses, and plaintiff leadership typically uses adverse outcomes to recalibrate case selection criteria and trial strategy rather than abandon the docket. Firms holding Paragard inventory should assess whether their specific cases are more or less analogous to the fact pattern that lost, since case quality variance inside any MDL is significant. The more actionable question is whether the verdict narrows the viable plaintiff profile in ways that affect how you screen and filter new intake going forward.
What screening and intake criteria should plaintiff firms use to identify the strongest Paragard cases given the current litigation posture?
The core liability theory in Paragard cases centers on device fracture during removal, so the most defensible cases involve documented evidence of breakage confirmed by imaging or operative report, a retained fragment, and a subsequent surgical intervention to remove it. Cases with clear medical record support, a short gap between removal and documented injury, and treatment by a named physician who can testify to causation will hold more settlement or trial value than cases relying on patient-reported symptoms alone. Firms should build intake questionnaires and medical record review protocols specifically around device fracture confirmation, fragment location, and the nature of corrective procedures performed.
